Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.6200 (1.72%) ($5.6200 - $5.6400) on Fri. Jul. 8, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.4% (three month average) | RSI | 80 | Latest Price | $5.6200(1.72%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 5.4% a day on average for past five trading days. | Weekly Trend | TGTX advances 12.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(78%) ARKG(75%) IBB(68%) ARKK(67%) XLC(62%) | Factors Impacting TGTX price | TGTX will decline at least -3.7% in a week (0% probabilities). TBT(-22%) UUP(-20%) USO(-15%) XLE(-9%) OIH(-9%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.7% (StdDev 7.4%) | Hourly BBV | 0.8 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.24(7.25%) | 10 Day Moving Average | $4.79(17.33%) | 20 Day Moving Average | $4.52(24.34%) | To recent high | -42.1% | To recent low | 50.5% | Market Cap | $712m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |